Hikma Introduces A Pair Of US Injectables
Builds On Strong Slate Of Launches Over Past Year
Hikma has added to its injectables portfolio in the US with the launches of dexmedetomidine and docetaxel.
You may also be interested in...
Hikma has delivered on one of its key US launches for 2021 by introducing its Kloxxado naloxone 8mg nasal spray for the emergency treatment of known or suspected opioid overdose, after the 505(b)(2) product was approved by the FDA earlier this year.
Hikma has added three products – a generic version of Banzel tablets and injectables ganciclovir and doxycycline – to its US portfolio.
Fresh from resuming launch of its generic version of Advair in the US, Hikma has also been boosted by an FDA approval for its 505(b)(2) naloxone 8mg nasal spray. Both developments are expected to drive the firm’s generics business to the top end of its guidance for 2021, management revealed.